Lisa Cook sues Trump over firing attempt, emergency hearing set
Haleon plc (LSE/NYSE:HLN), a global leader in consumer health, has disclosed its total number of shares and voting rights as of April 30, 2025, in a recent filing with the Securities and Exchange Commission. The company reports a total of 9,020,990,697 ordinary shares, each with a nominal value of £0.01. Among these, 4,080,205 shares are held in treasury.
As a result, the total number of ordinary shares carrying voting rights in the company stands at 9,016,910,492. This figure is significant for shareholders and others with notification obligations, as it serves as the denominator for calculating changes in their interest in the company, according to the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
The statement, signed by Company Secretary Amanda Mellor on May 1, 2025, also reminds those with notifiable interests in Haleon to communicate such information to the company secretary via the provided email address.
Haleon is known for its commitment to delivering better everyday health with humanity. Its portfolio spans major categories such as Oral Health, Pain Relief, Respiratory Health, Digestive Health, and Vitamins, Minerals, and Supplements. The company prides itself on trusted brands like Advil, Sensodyne, Panadol, and Centrum, which are based on trusted science and a deep understanding of consumer needs.
For further company information, Haleon directs interested parties to its website. The filing ensures that Haleon maintains transparency regarding its capital structure and provides necessary information for regulatory compliance and shareholder communication. This update is based on a press release statement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.